Clinical trials: sponsored by Henan Cancer Hospital
Ovarian Clear Cell Carcinoma
INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma
The goal of this phase 3 clinical trial is to evaluate whether QL1706 plus bevacizumab can effectively treat adult female patients (18 to <75 years old) with newly diagnosed FIGO stage IC-IV ovarian clear cell carcinoma.
- Trial name
- INVIGORATE (NCT07002346)
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CTLA-4), Bevacizumab, carboplatin
- Where
- China
- Volunteers
- 226 people
- Sponsor
- Tongji Hospital
Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
This is a prospective, randomized, open-label, active-controlled study to evaluate the efficacy and safety of Romiplostim N01 plus all-trans retinoic acid (ATRA) compared with Romiplostim N01 alone in adults with persistent…
- Conditions
- Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gastrointestinal Neoplasms, Pancreatic Cancer
- Trial name
- N01-A-PICIT-GI (NCT07586813)
- Testing
- Romiplostim N01, All-trans retinoic acid
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Peking University People's Hospital
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Acute Myeloid Leukemia (AML)
VABu Conditioning in Elderly AML HSCT
This is an open-label, multi-center, single-arm clinical study evaluating the efficacy and safety of the VABu conditioning regimen in elderly patients (≥60 years) with acute myeloid leukemia (AML) undergoing allogeneic…
- Trial name
- NCT07583888
- Testing
- VaBU
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
This is a prospective, randomized, open-label, active-controlled study to evaluate the efficacy and safety of Romiplostim N01 plus all-trans retinoic acid (ATRA) compared with Romiplostim N01 alone in adults with persistent…
- Conditions
- Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers, Ovarian Cancer
- Trial name
- N01-A-PICIT-GT (NCT07586826)
- Testing
- Romiplostim N01, All-trans retinoic acid
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Peking University People's Hospital
Leptomeningeal Metastasis From Lung Cancer
Exploration of the Application of Methotrexate-loaded Drug Vesicles in Intrathecal Injection for Meningeal Metastasis of Lung Cancer
This is a phase I/II, single-arm, open-label, single-center clinical trial to evaluate the safety, tolerability, and preliminary efficacy of intrathecal injection of methotrexate-loaded autologous tumor cell-derived…
- Trial name
- NCT07559097
- Testing
- Methotrexate-loaded vesicles
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Henan Cancer Hospital
Primary Immune Thrombocytopenia (ITP)
Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
This multicenter randomized, open-label study aimed to compare the efficacy and safety of eltrombopag combining rituximab with eltrombopag in China adult ITP patients .This study was be conducted in adult ITP patients who had not…
- Trial name
- NCT04518475
- Testing
- eltrombopag combining rituximab, eltrombopag
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Advanced Malignant Solid Tumor
PRL3-Zumab in Patients With Advanced Solid Tumors
This is a multicenter, Phase II, open-label, single-dose-level (6 mg/kg) study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumors.
- Trial name
- China Phase II (NCT07541001)
- Testing
- PRL3-ZUMAB
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Intra-IMMUSG Pte Ltd
Unknown Primary Tumors, DNA Methylation
PaCIFiC-CUP Classifies Cancer of Unknown Primary
This study aims to initially utilize machine learning on pan-cancer DNA methylation data from public databases to construct a DNA methylation classification model (PaCIFiC-CUP, pan-cancer integrated fingerprinting classifier of…
- Trial name
- NCT06140992
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Advanced Breast Cancer
A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer
To evaluate the efficacy and safety of toripalimab in combination with investigator-selected chemotherapy in patients with recurrent or metastatic HER2-negative breast cancer who have failed prior systemic therapy.
- Trial name
- 2025-370 (NCT07540533)
- Testing
- Toripalimab, TPC
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Henan Cancer Hospital
HER-2 Negative Breast Cancer
Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer
This study is a prospective, single-arm, open-label phase II study to evaluate the efficacy and safety of the combination of Utidelone and bevacizumab regimen in patients with ≥ 2 lines of HER-2 negative advanced breast cancer.
- Trial name
- NCT05398861
- Testing
- utidelone injection, Bevacizumab
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Henan Cancer Hospital
Marginal Zone Lymphoma
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Bortezomib and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients…
- Trial name
- NCT04433156
- Testing
- Bortezomib, Rituximab, Epirubicin
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Henan Cancer Hospital
SCLC, Extensive Stage
Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Small Cell Lung cancer (SCLC) is a highly aggressive tumor that accounts for about 15 percent of all lung cancer cases. SCLC disease progresses rapidly, and about 2/3 of the patients have extensive stage (ES-SCLC) at the time of…
- Trial name
- NCT04660097
- Testing
- Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
- Where
- 2 sites in China
- Volunteers
- 34 people
- Sponsor
- Henan Cancer Hospital
NSCLC
Clinical Effectiveness and Safety of SHR-A1811 in Chinese Patients With HER2-Altered NSCLC
SHR-A1811 is an approved therapy for non-small cell lung cancer (NSCLC) in China. Despite the clinical trial evidence, there is no real-world data of SHR-A1811 used in Chinese lung cancer patients with HER2 alteration.
- Trial name
- NCT07516015
- Testing
- No Drug
- Volunteers
- 1,000 people
- Sponsor
- Nanjing Tianyinshan Hospital
Breast Cancer
A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast Cancer
This study now plans to explore the efficacy and safety of hetrombopag in cancer therapy-induced thrombocytopenia in advanced breast cancer, so as to further guide the clinical application of hetrombopag in chemotherapy-induced…
- Trial name
- NCT05394285
- Testing
- Hetrombopag
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Follicular Lymphomas
ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma
Primary Objective: To compare the complete response rate (CR rate) after induction treatment between the ZR2 regimen and the R2 regimen.<br/><br/>Secondary Objectives: To compare the objective response rate (ORR) after induction…
- Trial name
- NCT07505849
- Testing
- Zanubrutinib+R2, R2
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- KeshuZhou
Metastatic Breast Cancer
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
This study aimed to evaluate the use of SHR-A1811 in HER2-expression Advanced Breast Cancer patients with brain metastases.
- Trial name
- NCT05769010
- Testing
- SHR-A1811, Pyrotinib, Bevacizumab
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Henan Cancer Hospital
Locally Advanced or Metastatic Solid Tumors
A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors
Brief Summary: This is a Phase I, first-in-human, open-label, multi-center study designed to explore the safety, tolerability, PK, and anti-tumor antitumor activity of ANS014004 monotherapy in subjects with locally advanced or…
- Trial name
- NCT06328439
- Testing
- ANS014004
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Avistone Biotechnology Co., Ltd.
MZL
CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma
This is a multicenter, real-world study on first-line CD20 monoclonal antibody-based regimens for treatment-naive marginal zone B-cell lymphoma based on risk stratification.
- Trial name
- NCT07492407
- Testing
- R2/BR/OR2
- Volunteers
- 131 people
- Sponsor
- Henan Cancer Hospital
T-cell Lymphoblastic Lymphoma
Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)
T-cell lymphoblastic lymphoma (T-LBL) is the second most common subtype of non-Hodgkin lymphoma (NHL) in children and adolescents. With current treatment, event-free survival (EFS) rates vary between 75%~85%.
- Trial name
- NCT05681260
- Testing
- Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Children's Cancer Group, China
Classical Hodgkin Lymphoma, Child
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
Generally, pediatric patients tolerate acute toxicities but are vulnerable to late effects. Thus, increasing chemotherapy intensity to achieve more rapid complete early response to limit radiation therapy is worth testing.
- Conditions
- Classical Hodgkin Lymphoma, Child, Adolescent, Young Adult
- Trial name
- NCT06563245
- Testing
- Brentuximab Vedotin for Injection, response-adapted radiation, Doxorubicin
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Children's Cancer Group, China